



Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India
Tel: +91-8532-238704, Fax: +91-8532-238876
Email: info@vbshilpa.com, Web: www.vbshilpa.com
CIN: L85110KA1987PLC008739

Date: 27 November 2024

To,

Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
MUMBAI-400 051

Dear Sir/Madam,

Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.

Ref: Stock Code: NSE: SHILPAMED/BSE-530549

.....

**USFDA Approval of NDA IMKELDI (Imatinib Oral Solution) Filled by our partner Shorla Oncology
developed by our JV Oncosol Limited**

This is to inform you that Shilpa Medicare's Joint Venture Oncosol (50:50 JV with Liqmeds Lifecare Limited, a Zydus group company and Koana Healthcare Limited, Shilpa Medicare group company) along with its partner Shorla Oncology announces that the USFDA has approved IMKELDI (imatinib oral solution), the first oral liquid form of imatinib to treat certain forms of leukemia and other cancers.

IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy. IMKELDI can help slow or prevent the growth of specific cancers, including chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, myelodysplastic syndrome /myeloproliferative disease (MDS/MPD), and gastrointestinal tumors (GIST).

In 2024, an estimated 9,280 people will be diagnosed with CML¹, over 10,000 with MDS/MPD², and up to 6,000 with GIST³ in the U.S. Despite the proven clinical benefits of imatinib, patient adherence can be an issue,^{4,5} underscoring a critical unmet need for a more accessible, patient-friendly oral solution delivery system.

Shilpa Medicare Limited, headquartered at Raichur, Karnataka, India, is a vertically integrated, manufacturer and distributor of quality drugs to global markets; specializing in the Oncology therapeutic segment and introducing novel drugs focusing on patient convenience and compliance.

For SHILPA MEDICARE LIMITED

Ritu Tiwary
Company Secretary & Compliance Officer



Shilpa Medicare Limited

Corporate & Admin Office:

“Shilpa House”, # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India
Tel: +91-8532-238704, Fax: +91-8532-238876
Email: info@vbshilpa.com, Web: www.vbshilpa.com
CIN: L85110KA1987PLC008739

Reference

1. Key Statistics for Chronic Myeloid Leukemia. American Cancer Society. Updated January 17, 2024. Accessed November 7, 2024. <https://www.cancer.org/cancer/types/chronic-myeloid-leukemia/about/statistics.html>
2. Key Statistics for Myelodysplastic Syndromes. American Cancer Society. Updated January 22, 2018. Accessed November 7, 2024. <https://www.cancer.org/cancer/types/myelodysplastic-syndrome/about/key-statistics.html>
3. Key Statistics for Gastrointestinal Stromal Tumors American Cancer Society. Updated January 26, 2021. Accessed November 7, 2024. <https://www.cancer.org/cancer/types/gastrointestinal-stromal-tumor/about/key-statistics.html>
4. Yanamandra U, Malhotra P, Sahu KK, et al. Variation in Adherence Measures to Imatinib Therapy. *J Glob Oncol.* 2018;4:1-10. doi:10.1200/JGO.2016.007906
5. Al-Barrak J, Cheung WY. Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia. *Support Care Cancer.* 2013;21(8):2351-2357. doi:10.1007/s00520-013-1831-6